{"protocolSection":{"identificationModule":{"nctId":"NCT01983644","orgStudyIdInfo":{"id":"REDIRECT"},"organization":{"fullName":"Jinling Hospital, China","class":"OTHER"},"briefTitle":"RECO Flow Restoration Device Versus Solitaire FR With the Intention for Thrombectomy Study","officialTitle":"RECO Flow Restoration Device Versus Solitaire FR With the Intention for Thrombectomy Study: a Prospective Randomised Control Trial(REDIRECT)","acronym":"REDIRECT"},"statusModule":{"statusVerifiedDate":"2016-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-09"},"primaryCompletionDateStruct":{"date":"2017-12","type":"ACTUAL"},"completionDateStruct":{"date":"2017-12","type":"ACTUAL"},"studyFirstSubmitDate":"2013-11-04","studyFirstSubmitQcDate":"2013-11-07","studyFirstPostDateStruct":{"date":"2013-11-14","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-07-23","lastUpdatePostDateStruct":{"date":"2018-07-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Xinfeng Liu","investigatorTitle":"Professor","investigatorAffiliation":"Jinling Hospital, China"},"leadSponsor":{"name":"Jinling Hospital, China","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"Endovascular therapy is increasingly used for patients with moderate-to-severe acute ischemic stroke.This study will compare the efficacy and safety of RECO(a novel, self-expanding stent retriever) with Solitaire FR within 8 hours of stroke onset caused by the large vessel occlusion.","detailedDescription":"RECO is a novel, self-expanding stent retriever, designed to yield rapid flow restoration in acute cerebral ischaemia. The proposed study is a multicenter, randomized, prospective, parallel-group, open-label clinical trial with a blinded outcome, to test the RECO(a novel, self-expanding stent retriever), as compared with Solitaire FR stent retriever."},"conditionsModule":{"conditions":["Ischemic Stroke"],"keywords":["acute ischemic stroke,endovascular recanalization","mechanical thrombectomy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":130,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"RECO thrombectomy","type":"EXPERIMENTAL","description":"IA thrombectomy is executed by RECO flow restoration device which is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.","interventionNames":["Device: RECO flow restoration device"]},{"label":"Solitaire FR thrombectomy","type":"ACTIVE_COMPARATOR","description":"IA thrombectomy is executed by Solitaire FR flow restoration device","interventionNames":["Device: Solitaire FR flow restoration device"]}],"interventions":[{"type":"DEVICE","name":"RECO flow restoration device","description":"RECO flow restoration device is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.","armGroupLabels":["RECO thrombectomy"],"otherNames":["RECO"]},{"type":"DEVICE","name":"Solitaire FR flow restoration device","description":"Solitaire FR flow restoration device has been approved by the FDA and CFDA.","armGroupLabels":["Solitaire FR thrombectomy"],"otherNames":["Solitaire FR"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Revascularization Status","description":"Revascularization, defined as at least TICI 2a in the vascular territory treated at end of the neuro interventional procedure Thrombolysis in Cerebral Infarction (TICI) grading system for perfusion (ie blood flow through a vessel) Grade 0:No Perfusion. No antegrade flow beyond the point of occlusion. Grade 1:Penetration With Minimal Perfusion. Grade 2:Partial Perfusion. Grade 2a:Only partial filling (\\<2/3) of the entire vascular territory is visualized. Grade 2b:Complete filling of all of the expected vascular territory is visualized, but slower . Grade 3:Complete Perfusion.","timeFrame":"Post-procedure, immediate=at the end of the procedure, per last angiogram during treatment"}],"secondaryOutcomes":[{"measure":"Clinical Outcomes at 90 Days","description":"Good clinical outcome is defined as an modified Rankin Scale (mRS) score of 0-2 at 90 days. mRS 0-2 indicates functional independence 0 - No symptoms.","timeFrame":"90-day"},{"measure":"intracranial hemorrhages","description":"Incidence of intracranial hemorrhages(ICH) within 24(-6/+12)hours post procedure","timeFrame":"24 hours"},{"measure":"all-cause mortality at 90 days","timeFrame":"procedure through 90 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. age (18-80 years)\n2. acute ischemic stroke\n3. within 8 hours after symptom onset\n4. a large-vessel confirmed by CTA/MRA (eg, internal carotid, middle cerebral M1 and/or M2 segments)\n5. NIHSS(≥8 and ≤24)\n6. patients or their legally authorised representatives provided signed, informed consent.\n\nExclusion Criteria:\n\n1. CT or MRI evidence of intracranial haemorrhage/tumor\n2. major ischaemic infarction (acute ischaemic change in more than a third of the middle cerebral artery territory)\n3. NIHSS(≥25 and ≤7)\n4. severe sustained hypertension (systolic blood pressure \\>185 mm Hg or diastolic blood pressure \\>110 mm Hg)\n5. baseline glucose concentrations of less than 2·7 mmol/L or higher than 21.6 mmol/L\n6. known haemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with an international normalised ratio of more than 1.7\n7. treatment with heparin within 48 h with a partial thromboplastin time more than two times the laboratory normal, baseline platelet count of less than 100×10\\^9/L\n8. history of severe allergy (worse than rash) to contrast medium or nitinol\n9. pregnancy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Xinfeng Liu, MD","affiliation":"Department of Neurology, Jinling Hospital, Nanjing 210002, China","role":"STUDY_CHAIR"}],"locations":[{"facility":"Daping Hospital","city":"Chongqing","state":"Chongqing","country":"China","geoPoint":{"lat":29.56278,"lon":106.55278}},{"facility":"Fuzhou General Hospital","city":"Fuzhou","state":"Fujian","country":"China","geoPoint":{"lat":26.06139,"lon":119.30611}},{"facility":"Zhongshan Hospital of Xiamen University","city":"Xiamen","state":"Fujian","country":"China","geoPoint":{"lat":24.47979,"lon":118.08187}},{"facility":"Zhongnan Hospital of Wuhan University","city":"Wuhan","state":"Hubei","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"First People's Hospital of Changzhou","city":"Changzhou","state":"Jiangsu","country":"China","geoPoint":{"lat":31.77359,"lon":119.95401}},{"facility":"Department of Neurology, Jinling Hospital, Nanjing University School of Medicine","city":"Nanjing","state":"Jiangsu","zip":"210002","country":"China","geoPoint":{"lat":32.06167,"lon":118.77778}},{"facility":"Affiliated Hospital of Nantong University","city":"Nantong","state":"Jiangsu","country":"China","geoPoint":{"lat":32.03028,"lon":120.87472}},{"facility":"Second Affiliated Hospital of Soochow University","city":"Suzhou","state":"Jiangsu","country":"China","geoPoint":{"lat":31.30408,"lon":120.59538}},{"facility":"Yangzhou First People's Hospital","city":"Yangzhou","state":"Jiangsu","country":"China","geoPoint":{"lat":32.39722,"lon":119.43583}},{"facility":"Affiliated Hospital of Qingdao University","city":"Qingdao","state":"Shandong","country":"China","geoPoint":{"lat":36.06488,"lon":120.38042}}]},"referencesModule":{"references":[{"pmid":"32502991","type":"DERIVED","citation":"Cao J, Lin H, Lin M, Ke K, Zhang Y, Zhang Y, Zheng W, Chen X, Wang W, Zhang M, Xuan J, Peng Y; REDIRECT Trial Investigators. RECO Flow Restoration Device Versus Solitaire FR With the Intention for Thrombectomy Study (REDIRECT): a prospective randomized controlled trial. J Neurosurg. 2020 Jun 5;134(5):1569-1577. doi: 10.3171/2020.3.JNS193356."},{"pmid":"26514251","type":"DERIVED","citation":"Jiang Y, Li Y, Xu X, Yu Y, Liu W, Liu X. An in vitro porcine model evaluating a novel stent retriever for thrombectomy of the common carotid artery. Catheter Cardiovasc Interv. 2016 Feb 15;87(3):457-64. doi: 10.1002/ccd.26285. Epub 2015 Oct 30."}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000020521","term":"Stroke"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}